A Phase I/IIA Open-label Dose-Finding Study With Subsequent Double-blind, Placebo-controlled, Randomized Study of L-citrulline in Sickle Cell Disease Presenting to Emergency Department (ED) in Vaso Occlusive Crisis (VOC) in Children, Adolescents and Young Adults (6 to 21 Years)
Latest Information Update: 24 Aug 2023
At a glance
- Drugs Citrulline (Primary)
- Indications Vaso-occlusive crisis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Asklepion Pharmaceuticals
- 17 Aug 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 17 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 27 Jul 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.